Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated at Guggenheim

Guggenheim started coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $22.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on VYGR. Citigroup assumed coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They issued a buy rating and a $16.00 price objective for the company. StockNews.com upgraded shares of Voyager Therapeutics from a hold rating to a buy rating in a report on Saturday, March 9th. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an equal weight rating to an overweight rating and upped their price objective for the stock from $9.00 to $14.00 in a report on Tuesday, January 2nd. Finally, HC Wainwright started coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They set a buy rating and a $30.00 price target for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics has an average rating of Moderate Buy and a consensus price target of $19.33.

Voyager Therapeutics Stock Down 2.6 %

Voyager Therapeutics stock opened at $9.31 on Tuesday. The company’s fifty day simple moving average is $8.41 and its 200-day simple moving average is $7.86. Voyager Therapeutics has a 12 month low of $6.06 and a 12 month high of $14.34. The stock has a market cap of $505.53 million, a P/E ratio of 3.01 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. The firm had revenue of $90.06 million during the quarter, compared to analysts’ expectations of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. On average, equities research analysts expect that Voyager Therapeutics will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VYGR. Gladius Capital Management LP acquired a new position in shares of Voyager Therapeutics during the third quarter valued at about $25,000. Ameritas Investment Partners Inc. acquired a new position in shares of Voyager Therapeutics during the second quarter valued at about $30,000. AJOVista LLC acquired a new position in shares of Voyager Therapeutics during the fourth quarter valued at about $39,000. UBS Group AG acquired a new position in shares of Voyager Therapeutics during the first quarter valued at about $39,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Voyager Therapeutics during the fourth quarter valued at about $43,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.